文献速递放射性药物与辐射防护

18F-GP1正电子发射断层显像用于急性静脉血栓栓塞症的糖蛋白IIb/IIIa受体显像:一项开放标签、非随机、首次人体1期研究

Glycoprotein IIb/IIIa receptor imaging with 18F-GP1 positron emission tomography for acute venous thromboembolism: an open-label, non-randomized, first-in-human phase 1 study.
PubMed 文献 · J Nucl Med · 2018-06-29

本研究为开放标签、非随机、首次人体1期研究,纳入20例急性下肢深静脉血栓或急性肺栓塞患者,注射250 MBq 18F-GP1后行动态全身PET/CT,评估血栓灶检出率及安全性、生物分布、药代动力学和代谢。18F-GP1 PET/CT耐受良好,无药物相关不良事件,全部20例患者均检出栓塞灶;血管水平分析显示深静脉血栓检出率为89%(68/76),肺栓塞为60%(146/245),并在常规影像未检出的32支血管中显示摄取增高。

要点

  • 18F-GP1 PET/CT在全部20例急性静脉血栓栓塞症患者中检出栓塞灶。
  • 血管水平深静脉血栓检出率89%(68/76),肺栓塞检出率60%(146/245)。
  • 18F-GP1 PET/CT在常规影像未检出的32支血管中显示摄取增高。

核心结论

  • 18F-GP1是一种有前景的用于急性静脉血栓栓塞症显像的PET示踪剂。
  • 18F-GP1 PET/CT可能识别常规影像有局限的下肢远端静脉血栓。

研究设计与样本

  • 开放标签、非随机、首次人体1期研究。
  • 纳入有急性下肢深静脉血栓或急性肺栓塞症状或体征、且在18F-GP1 PET/CT前14天内经常规影像确认血栓灶的患者,深静脉血栓10例、肺栓塞10例。
  • 注射250 MBq 18F-GP1后采集动态全身PET/CT图像,最长至注射后140分钟。

主要发现

  • 18F-GP1 PET/CT耐受良好,无药物相关不良事件。
  • 脾、肾和血池初始摄取高,随后快速清除。
  • 全部患者图像质量优良并可判读。
  • 18F-GP1 PET/CT在全部20例深静脉血栓或肺栓塞患者中检出栓塞灶。
  • 血管水平分析:深静脉血栓检出率89%(68/76),肺栓塞检出率60%(146/245)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-GP1 is a derivative of elarofiban with a high affinity to activated platelet glycoprotein IIb/IIIa (GPIIb/IIIa) and favorable in vivo characteristics for thrombus imaging in preclinical models. We aimed to explore the detection rate of thromboembolic foci with 18F-GP1 positron emission tomography/computed tomography (PET/CT) in patients with acute venous thromboembolism (VTE), and to evaluate the safety, biodistribution, pharmacokinetics, and metabolism of 18F-GP1. Methods: We studied patients who had signs or symptoms of acute deep vein thrombosis (DVT) of the leg or acute pulmonary embolism (PE) within 14 days prior to 18F-GP1 PET/CT, and had thromboembolic foci confirmed by conventional imaging (n = 10 for DVT and n = 10 for PE). Dynamic whole-body PET/CT images were acquired for up to 140 minutes after injection of 250 MBq of 18F-GP1. Results:18F-GP1 PET/CT was well tolerated without any drug-related adverse events, and showed high initial uptake in spleen, kidney, and blood pool, followed by rapid clearance. The overall image quality was excellent and allowed interpretation in all patients. 18F-GP1 PET/CT identified thromboembolic foci in all 20 patients with either DVT or PE. Vessel-level analysis revealed that 18F-GP1 PET/CT detected 89% (68/76) of vessels with DVT, and 60% (146/245) for PE. Importantly, 18F-GP1 PET/CT showed increased uptake in 32 vessels that were not detected by conventional imaging, of which 25 were located in distal veins of the lower extremity in 12 patients. A positive correlation was found between 18F-GP1 uptake and P-selectin-positive circulating platelets (r = 0.656, P = 0.002). Conclusion:18F-GP1 is a promising PET tracer for imaging acute VTE in patients. 18F-GP1 PET/CT may identify thrombi in distal veins of the leg, where conventional imaging has limitations.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kim C, Lee JS, Han Y, et al. Glycoprotein IIb/IIIa receptor imaging with 18F-GP1 positron emission tomography for acute venous thromboembolism: an open-label, non-randomized, first-in-human phase 1 study. J Nucl Med. 2018. PMID: 29959214. doi:10.2967/jnumed.118.212084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。